The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
UK MHRA grants conditional marketing authorization to obecabtagene autoleucel for the treatment of adult patients with R/R B-ALL
On April 28, 2025, the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization to obecabtagene autoleucel (obe-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).1 This approval was based on promising results from the FELIX trial (NCT04404660).1
FELIX study1
FELIX is an ongoing phase Ib/II, open-label, multicenter, single-arm study designed to evaluate the safety and efficacy of obe-cel in adult patients with B-ALL.2 The ALL Hub previously reported on the efficacy and safety and tumor burden-guided dosing data for obe-cel from the FELIX study. The key results in evaluable patients with R/R B-ALL (n = 127) were as follows:1
- The complete response/complete response with incomplete hematological recovery for patients who received at least one infusion of obe-cel was 76.6%.
- The median response duration for all infused patients was 21.2 months.
- The median event-free survival (EFS) was 11.9 months, and the estimated 6- and 12-month EFS rates were 65.4% and 49.5%, respectively.
- The most common non-laboratory Grade ≥3 or higher adverse reactions were infections: pathogen unspecified (32%), febrile neutropenia (24%), and bacterial infectious disorders (11%). Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were reported in 68.5% (Grade ≥3 in 2.4%) and 22.8% (Grade ≥3 in 7%) of patients, respectively.
Obe-cel received marketing approval by the U.S. Food and Drug Administration (FDA) as a consolidation therapy for the treatment of adult patients with R/R B-ALL on November 8, 2024.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?
